Gambaran Umum
Ang OncoSec Medical Incorporated, na nakabase sa United States, ay nagpapatakbo sa loob ng sektor ng biotechnology, pangunahing nakikibahagi sa pagbuo ng mga novel therapies para sa paggamot sa kanser sa pamamagitan ng immunotherapy. Nakatuon ang kumpanya sa paggamit ng proprietary technology nito, TAVO™ (tavokinogene telseplasmid), isang plasmid DNA delivery formulation, na ginagamit kasabay ng electroporation delivery system nito upang mapahusay ang lokal at systemic na epekto ng immunotherapy. Kasama sa isang pangunahing proyekto ang isang klinikal na programa na tinatasa ang TAVO™ kasama ng mga checkpoint inhibitor para sa paggamot sa metastatic melanoma, na itinuturing na partikular na lumalaban na uri ng kanser sa mga kumbensyonal na therapy. Ang diskarte ng OncoSec ay umiikot sa pagtugon sa hindi pa natutugunan na mga medikal na pangangailangan sa oncology, nagsusumikap na magbigay ng mga makabago at mabisang paggamot na maaaring mapabuti ang kaligtasan at kalidad ng buhay para sa mga pasyente ng cancer.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk OncoSec Medical Incorporated per 2023 Jan 31 adalah -32.65 MM.
- Nilai net income untuk OncoSec Medical Incorporated per 2023 Jan 31 adalah -29.39 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2023-01-31 | -32.65 | -29.39 | |
2022-10-31 | -34.40 | -32.43 | |
2022-07-31 | -37.01 | -34.18 | |
2022-04-30 | -40.96 | -37.76 | |
2022-01-31 | -43.65 | -40.95 | |
2021-10-31 | -46.26 | -41.75 | |
2021-07-31 | -49.38 | -45.17 | |
2021-04-30 | -45.71 | -42.34 | |
2021-01-31 | -45.10 | -42.79 | |
2020-10-31 | -46.61 | -45.72 | |
2020-07-31 | |||
2020-04-30 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk OncoSec Medical Incorporated pada 2023 Jan 31 adalah -14.77.
- laba per saham yang terdilusi untuk OncoSec Medical Incorporated pada 2023 Jan 31 adalah -14.77.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2023-01-31 | -14.77 | -14.77 |
2022-10-31 | -18.13 | -18.13 |
2022-07-31 | -19.13 | |
2022-04-30 | -21.18 | -21.18 |
2022-01-31 | -23.30 | -23.30 |
2021-10-31 | -25.51 | -25.51 |
2021-07-31 | -30.20 | |
2021-04-30 | -32.24 | -32.24 |
2021-01-31 | -37.57 | -37.57 |
2020-10-31 | -48.91 | -48.91 |
2020-07-31 | -56.22 | |
2020-04-30 | -67.82 | -67.82 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk OncoSec Medical Incorporated per 2023 Jan 31 adalah -24.99 MM.
- Nilai cash from investing activities untuk OncoSec Medical Incorporated per 2023 Jan 31 adalah -0.01 MM.
- Nilai kas dari aktivitas pendanaan untuk OncoSec Medical Incorporated per 2023 Jan 31 adalah 3.54 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2023-01-31 | -24.99 | -0.01 | 3.54 |
2022-10-31 | -28.40 | -0.24 | -1.14 |
2022-07-31 | -32.14 | -0.24 | -1.16 |
2022-04-30 | -33.63 | -0.29 | -0.91 |
2022-01-31 | -41.09 | -0.79 | 6.83 |
2021-10-31 | -41.92 | -0.80 | 54.46 |
2021-07-31 | -41.79 | -0.80 | 68.21 |
2021-04-30 | -42.75 | -0.75 | 67.83 |
2021-01-31 | -38.16 | -0.25 | 89.51 |
2020-10-31 | -34.75 | 41.84 | |
2020-07-31 | |||
2020-04-30 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2023-01-31 | |||
2022-10-31 | |||
2022-07-31 | -0.00 | 0.00 | 0.00 |
2022-04-30 | -0.00 | 0.00 | 0.00 |
2022-01-31 | |||
2021-10-31 | -0.00 | 0.00 | 0.00 |
2021-07-31 | -0.00 | 0.00 | 0.00 |
2021-04-30 | |||
2021-01-31 | -0.00 | 0.00 | 0.00 |
2020-10-31 | -0.00 | 0.00 | 0.00 |
2020-07-31 | |||
2020-04-30 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2023-01-31 | ||
2022-10-31 | ||
2022-07-31 | 3.03 | 2.96 |
2022-04-30 | 2.30 | 2.21 |
2022-01-31 | ||
2021-10-31 | 1.20 | 1.02 |
2021-07-31 | 0.89 | 0.82 |
2021-04-30 | ||
2021-01-31 | 2.05 | 1.76 |
2020-10-31 | 2.28 | 1.98 |
2020-07-31 | ||
2020-04-30 |
Efektivitas Manajemen
- roe untuk OncoSec Medical Incorporated pada 2023 Jan 31 adalah -1.48.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2023-01-31 | -1.48 | ||||
2022-10-31 | -1.13 | ||||
2022-07-31 | -0.59 | -0.80 | -1.54 | -1.42 | -1.37 |
2022-04-30 | -0.59 | -0.85 | -1.28 | -1.10 | -1.29 |
2022-01-31 | -0.85 | ||||
2021-10-31 | -1.51 | -3.26 | -0.90 | 0.51 | -0.83 |
2021-07-31 | -1.08 | -1.95 | -0.71 | 0.41 | -0.72 |
2021-04-30 | -1.95 | ||||
2021-01-31 | -1.97 | -2.99 | -1.89 | 0.29 | -1.44 |
2020-10-31 | -1.41 | -1.74 | -1.95 | -0.22 | -1.53 |
2020-07-31 | -1.74 | ||||
2020-04-30 | -1.93 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2023-01-31 | |||
2022-10-31 | |||
2022-07-31 | |||
2022-04-30 | |||
2022-01-31 | |||
2021-10-31 | |||
2021-07-31 | |||
2021-04-30 | |||
2021-01-31 | |||
2020-10-31 | |||
2020-07-31 | |||
2020-04-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1444307 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |